Physician profile
Shahrokh Javaheri
NPI 1407829757
$403,601.67
in general payments reported to CMS, 2019-2025
20 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $46K · 2021: $22K · 2022: $63K · 2023: $115K · 2024: $48K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Consulting Fee: $67K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Travel and Lodging: $12K · Honoraria: $11K · Food and Beverage: $9,668 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,203.13 |
| Consulting Fee | $66,980.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,500.00 |
| Travel and Lodging | $11,608.13 |
| Honoraria | $10,550.00 |
| Food and Beverage | $9,668.44 |
| Education | $391.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $203,530.07 | 2019-2025 | Remede System |
| Idorsia Pharmaceuticals US INC | $123,061.20 | 2022-2024 | Quviviq, Tryvio |
| Jazz Pharmaceuticals INC. | $23,489.14 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $18,655.64 | 2023-2025 | Lumryz |
| Fisher & Paykel Healthcare Limited | $12,996.95 | 2019 | |
| Philips North America LLC | $7,909.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $6,684.93 | 2019-2023 | Belsomra |
| Harmony Biosciences LLC | $2,635.62 | 2020-2025 | Wakix |
| Eisai INC. | $1,700.00 | 2021 | |
| Eli Lilly and Company | $800.00 | 2023 | |
| Axsome Therapeutics, INC. | $610.20 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $509.47 | 2023-2025 | Inspire |
| Novo Nordisk INC | $279.23 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $223.21 | 2025 | |
| Avita Medical Americas, LLC | $175.62 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $138.01 | 2025 | Zepbound |
| Fisher & Paykel Healthcare INC | $97.30 | 2020-2025 | Fisher & Paykel Healthcare |
| Resmed Corp | $39.51 | 2023-2024 | |
| Itamar Medical INC | $36.78 | 2024 | Watchpatone |
| Vanda Pharmaceuticals INC. | $28.89 | 2022-2023 | Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahrokh Javaheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.